Assessing Vaccine Efficacy and Effectiveness in ... - The INCLEN Trust
Assessing Vaccine Efficacy and Effectiveness in ... - The INCLEN Trust
Assessing Vaccine Efficacy and Effectiveness in ... - The INCLEN Trust
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Assess<strong>in</strong>g</strong> <strong>Vacc<strong>in</strong>e</strong> <strong>Efficacy</strong> <strong>and</strong><br />
<strong>Effectiveness</strong> <strong>in</strong> Observational Studies<br />
Steven Black, MD<br />
Professor of Pediatrics<br />
Center for Global Health<br />
University of C<strong>in</strong>c<strong>in</strong>nati Children’s Hospital<br />
C<strong>in</strong>c<strong>in</strong>nati, Ohio USA
Why do we care?<br />
Why are observational assessments of effectiveness useful?<br />
• Cl<strong>in</strong>ical trials may not give a “true” assessment<br />
of the vacc<strong>in</strong>e effect<br />
– Population differences<br />
– Cl<strong>in</strong>ical trial exclusion criteria<br />
– Lack of measurement of some effects that might<br />
not have been anticipated or that can not be<br />
observed <strong>in</strong> a cl<strong>in</strong>ical trial<br />
• Indirect effects
<strong>Efficacy</strong> Versus <strong>Effectiveness</strong><br />
• <strong>Efficacy</strong>: the specific reduction <strong>in</strong> attack rate<br />
between the vacc<strong>in</strong>ated <strong>and</strong> unvacc<strong>in</strong>ated<br />
group <strong>in</strong> a cl<strong>in</strong>ical trial:<br />
ve= (1-Rv/Rp) x 100%<br />
• <strong>Effectiveness</strong>: reduction <strong>in</strong> cl<strong>in</strong>ical events that<br />
might be expected to be associated with the<br />
disease but could also be caused by other<br />
agents.
Observational Studies: <strong>The</strong> Good News<br />
• Observational studies have the advantage of<br />
be<strong>in</strong>g able to assess impact <strong>in</strong> the actual<br />
population of <strong>in</strong>terest.<br />
• Results can be used to evaluate or confirm cost<br />
effectiveness estimates.<br />
• Changes <strong>in</strong> vacc<strong>in</strong>e effect can be tracked over<br />
time.<br />
• Unanticipated outcomes can be assessed.<br />
• Impact of partial or off schedule dos<strong>in</strong>g can be<br />
assessed.
Observational Studies: <strong>The</strong> Bad News<br />
• Observational studies are observational !!<br />
– <strong>The</strong>re is no predef<strong>in</strong>ed control group.<br />
– Non vacc<strong>in</strong>ees tend to be different than vacc<strong>in</strong>ees.<br />
– Historical controls can <strong>in</strong>troduce the risk of<br />
confound<strong>in</strong>g.<br />
• Other non-vacc<strong>in</strong>e secular changes can<br />
dramatically impact assessment<br />
– Cyclic changes <strong>in</strong> serotype distribution unrelated to<br />
vacc<strong>in</strong>e.<br />
– Changes <strong>in</strong> cl<strong>in</strong>ical practice unrelated to vacc<strong>in</strong>e.
QUESTION<br />
Changes <strong>in</strong> disease <strong>in</strong>cidence or serotype<br />
distribution can be impacted by:<br />
a. <strong>Vacc<strong>in</strong>e</strong><br />
b. Antibiotic use<br />
c. Secular trends<br />
d. all of the above<br />
e. Not a, b or c.
Observational Studies to Assess<br />
<strong>Efficacy</strong><br />
Positive Examples
Cases per 100,000<br />
Rates of <strong>in</strong>vasive pneumococcal disease<br />
among children
Cases/100,000 population<br />
Rates of Penicill<strong>in</strong>-Nonsusceptible IPD<br />
by Age Group<br />
ABCs 1998/1999 <strong>and</strong> 2004<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
1998/9 2004<br />
55% reduction<br />
Rate per 100,000 population<br />
Clos<strong>in</strong>g the Gap<br />
Rates of IPD <strong>in</strong> Australian children
Cases/100,000 population<br />
Example of an Indirect Population Effect<br />
Invasive Pneumococcal Disease<br />
40<br />
35<br />
30<br />
25<br />
20<br />
15<br />
10<br />
5<br />
0<br />
1998<br />
1999<br />
Adults 65 years <strong>and</strong> older, 1998-2007<br />
PCV-7<br />
<strong>in</strong>troduced<br />
2000<br />
2001<br />
2002<br />
2003<br />
2004<br />
2005<br />
Nonvacc<strong>in</strong>e<br />
types<br />
PCV-7<br />
types<br />
2006<br />
2007<br />
2007 vs.<br />
basel<strong>in</strong>e<br />
+44%<br />
-92%<br />
basel<strong>in</strong>e<br />
Slide courtesy of Cynthia Whitney, CDC<br />
Year<br />
11
HPA Men<strong>in</strong>gococcal C Surveillance
Resurgence of Hib Disease <strong>in</strong> the UK<br />
BMJ VOLUME 329, 18 SEPTEMBER 2004
Why were these studies successful?<br />
• Invasive disease assessment<br />
– IPD is usually non-dsicretionary. That is, there is<br />
relatively little variation over time <strong>in</strong> the tendency<br />
to seek care.<br />
• Surveillance network was <strong>in</strong> place <strong>and</strong> stable<br />
for years prior to the assessment<br />
– Laboratory <strong>and</strong> case ascerta<strong>in</strong>ment criteria did not<br />
change over time
Observational Studies to Assess<br />
<strong>Efficacy</strong><br />
Precautions
Red Flags for Observational<br />
<strong>Effectiveness</strong> Studies<br />
• Discretionary outcomes: Health care<br />
utilization patterns may change the criteria for<br />
seek<strong>in</strong>g medical care<br />
– New guidel<strong>in</strong>es for otitis media treatment<br />
– Stricter criteria for admission for pneumonia<br />
• Lack of awareness or controll<strong>in</strong>g for other<br />
factors<br />
– Antibiotic usage <strong>and</strong> serotype replacement.
Examples of Possibly Problematic<br />
Observational <strong>Effectiveness</strong> Studies
Examples of Possibly Problematic<br />
Observational <strong>Effectiveness</strong> Studies<br />
Pneumococcal Serotype Replacement
Non-<strong>Vacc<strong>in</strong>e</strong> Serotype Replacement
Secular trends <strong>in</strong> Spa<strong>in</strong><br />
Spa<strong>in</strong>: temporal trends of serotypes<br />
that were (a) <strong>in</strong>cluded <strong>and</strong> (b) the<br />
most prevalent serotypes not <strong>in</strong>cluded<br />
<strong>in</strong> PCV7 among <strong>in</strong>vasive isolates, 1979<br />
to 2007<br />
Some “replacement” stra<strong>in</strong>s were<br />
<strong>in</strong>creas<strong>in</strong>g <strong>in</strong> prevalence years prior to<br />
PCV <strong>in</strong>troduction <strong>in</strong> 2001<br />
Fenoll et al. J Cl<strong>in</strong> Micro 2009; 47: 1012-1020
% of all IPD <strong>in</strong> children < 5 yrs<br />
S<strong>in</strong>gle Clonal Expansion of S. pneumoniae Serotype 19A <strong>in</strong> Korean<br />
Children Before PCV7 Introduction<br />
25<br />
20<br />
23<br />
• All 19A isolates were MDR<br />
• All isolates from 2001 exhibited<br />
Sequence Type (ST) 320<br />
15<br />
10<br />
5<br />
0<br />
0<br />
8<br />
1991-1994 1995-1999 2000-2006<br />
A dramatic <strong>in</strong>crease <strong>in</strong> rates of IPD<br />
caused by antibiotic-resistant<br />
serotype 19A<br />
can occur without vacc<strong>in</strong>ation<br />
Year<br />
Choi et al, 45 th IDSA abstract #202, 2007
Examples of Possibly Problematic<br />
Observational <strong>Effectiveness</strong> Studies<br />
Pneumonia
PCV7 Reduces Pneumonia Admissions<br />
(2004)<br />
65% 73%<br />
39%<br />
30%<br />
17%<br />
26%<br />
41,000 pneumonia admissions<br />
averted among < 2 yo ?????<br />
Grijalva Lancet 2007;369:1179-86.
Hospital Utilization Management<br />
Can Change Rates of Hospitalized Disease
Examples of Possibly Problematic<br />
Observational <strong>Effectiveness</strong> Studies<br />
Otitis Media
Impact of PCV7 on Otitis Media<br />
Grijilva et al Pediatrics Sept 2006
Changes <strong>in</strong> Treatment Guidel<strong>in</strong>es for Otitis Media:<br />
Another Cause of Reduced Medical Visits
Observational <strong>Effectiveness</strong><br />
Studies<br />
A MORE COMPLICATED EXAMPLE:<br />
COMPARATIVE EFFECTIVENESS OF<br />
TWO INFLUENZA VACCINES
Comparative <strong>Effectiveness</strong> of Adjuvanted <strong>and</strong><br />
Unadjuvanted Influenza <strong>Vacc<strong>in</strong>e</strong> <strong>in</strong> the Elderly<br />
• Elderly <strong>in</strong>dividuals are relatively unresponsive<br />
to st<strong>and</strong>ard doses of <strong>in</strong>fluenza vacc<strong>in</strong>e<br />
• Elderly <strong>in</strong>dividuals are at higher risk of<br />
complications of <strong>in</strong>fluenza<br />
• Adjuvanted <strong>in</strong>fluenza vacc<strong>in</strong>es are more<br />
immunogenic <strong>in</strong> the elderly<br />
• Study question: Are adjuvanted <strong>in</strong>fluenza<br />
vacc<strong>in</strong>es more effective <strong>in</strong> the prevention of<br />
<strong>in</strong>fluenza?
Comparative <strong>Effectiveness</strong> of Adjuvanted <strong>and</strong><br />
Unadjuvanted Influenza <strong>Vacc<strong>in</strong>e</strong> <strong>in</strong> the Elderly<br />
• <strong>The</strong> LIVE study was conducted <strong>in</strong> Italy to compare<br />
MF-59 adjuvanted <strong>in</strong>fluenza vacc<strong>in</strong>e to nonadjuvanted<br />
<strong>in</strong>fluenza vacc<strong>in</strong>e<br />
• Problem: As <strong>in</strong>fluenza vacc<strong>in</strong>e was rout<strong>in</strong>ely<br />
recommended AND adjuvanted vacc<strong>in</strong>e was<br />
preferentially recommended for higher risk<br />
elderly, it was not considered ethical to conduct a<br />
r<strong>and</strong>omized study<br />
• Solution: conduct an observational study <strong>and</strong><br />
adjust for confound<strong>in</strong>g.
Comparative <strong>Effectiveness</strong> of Adjuvanted <strong>and</strong><br />
Unadjuvanted Influenza <strong>Vacc<strong>in</strong>e</strong> <strong>in</strong> the Elderly
Observational <strong>Effectiveness</strong> Studies<br />
• Work best for non-discretionary outcome such as<br />
those requir<strong>in</strong>g hospitalization (sepsis,<br />
men<strong>in</strong>gitis)<br />
• Can assess population effects such as herd<br />
immunity<br />
• Are subject to confound<strong>in</strong>g by secular trends<br />
– Chang<strong>in</strong>g guidel<strong>in</strong>es<br />
– Other factors (antibiotics, cyclic patterns of disease)<br />
• Overall are very useful, but require more<br />
thoughtful <strong>in</strong>terpretation than a RCT.
QUESTION<br />
Which statement is NOT true about observational<br />
studies<br />
a. Provide a real life picture of a vacc<strong>in</strong>e’s effect<br />
b. Monitor chang<strong>in</strong>g effectiveness over time<br />
c. Should only be done if cl<strong>in</strong>ical trials are not<br />
possible<br />
d. Are subject to confound<strong>in</strong>g
Conclusions<br />
• Observational studies offer the opportunity to assess<br />
real life public health impact.<br />
• Observations, both positive <strong>and</strong> negative, are subject<br />
to confound<strong>in</strong>g<br />
– By changes <strong>in</strong> population composition<br />
– By other changes <strong>in</strong> medical care practice<br />
– By temporal trends.<br />
• <strong>The</strong>se studies are none the less <strong>in</strong>dispensible<br />
– Allow ability to assess unanticipated changes <strong>in</strong> vacc<strong>in</strong>e<br />
efficacy or epidemiology<br />
– Can <strong>in</strong>form future vacc<strong>in</strong>e development <strong>and</strong> prioritization